Allogeneic Hematopoietic Cell Transplantation to Correct the Biochemical Defect and Create Tolerance to Donor Tissue in Subjects With Epidermolysis Bullosa.

Trial Profile

Allogeneic Hematopoietic Cell Transplantation to Correct the Biochemical Defect and Create Tolerance to Donor Tissue in Subjects With Epidermolysis Bullosa.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 08 Feb 2013

At a glance

  • Drugs Busulfan (Primary) ; Cyclophosphamide (Primary) ; Fludarabine (Primary) ; Mycophenolate mofetil
  • Indications Graft-versus-host disease; Skin cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 31 Jan 2012 Planned end date changed from 1 May 2017 to 1 Aug 2011 as reported by ClinicalTrials.gov.
    • 31 Jan 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top